Latest Leadership Transitions News

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Australian Critical Minerals has appointed geologist Allister Caird as a Non-Executive Director, alongside key leadership shifts including Dean DeLargie's move to Executive Chairman. These changes underscore the company’s strategic push in critical minerals exploration across Australia and Peru.

Life360, Inc. reported robust Q3 2025 financial results driven by subscription and partnership revenue growth, alongside a leadership transition and strategic capital moves. The company also announced a major acquisition to bolster its advertising platform.

Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.

Iress launches a comprehensive FY26 business efficiency program targeting a 25% cash EBITDA margin, while narrowing its FY25 guidance and welcoming a new CEO.

TT Investments has launched an unconditional $0.31 per security takeover bid for 360 Capital Group, aiming to delist the company from the ASX. The Independent Board Committee recommends acceptance amid significant premiums and looming governance changes.

Nine Entertainment reported a resilient FY25 with strategic transformation gains, digital subscription growth, and a major capital return following the sale of its Domain stake. Leadership changes and regulatory challenges frame its path forward.

AVITA Medical reported an 18% revenue increase in Q3 2025 driven by new product launches and deeper market penetration, while continuing to face net losses and credit covenant challenges. The company also announced a CEO departure and interim leadership appointment.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

FSI’s FY2025 portfolio posted a modest 5.0% return, trailing the ASX All Ordinaries Index, while maintaining dividend growth and planning a strategic move into pre-IPO investments.

Dr Andrew Blattman, who has led IPH Limited through nearly a decade of transformative growth and international expansion, will retire as CEO in the second half of 2026. The Board has initiated a search for his successor to ensure a smooth leadership transition.